GPhA Warns FDA On ANDA Review Transparency
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee negotiations could be 'lengthy and very detailed' unless FDA does 'the right thing' and implements 'effective' communication practices, generic trade group says.
You may also be interested in...
Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
Industry dismay at slow pace of ANDA approvals and FDA communications in early years of first user fee agreement factored into GDUFA II negotiations.
Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I
Industry dismay at slow pace of ANDA approvals and FDA communications in early years of first user fee agreement factored into GDUFA II negotiations.
GDUFA Stakeholder Deadline May Come After Negotiations Conclude
Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.